Drugs / CD7 CAR-T cell
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07476027 | Mar 2026 → Apr 2029 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06585345 | Feb 2024 → Dec 2027 expected | acute leukemia | The General Hospital of Western Theater Command | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD7 CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585345 ↗ |
| Modality | Cell therapy | “CD7 CAR-T cells” NCT06585345 ↗ |
| Route | Intravenous | “Split intravenous infusion of CD7 CAR-T cells” NCT06585345 ↗ |
| Target | CD7 | “CD7 CAR-T cells” NCT07476027 ↗ |